GPT and anemia: The most frequent AEs in patients of the RT plus lenvatinib group were increased aspartate aminotransferase level (n = 28, 58.3%), increased alanine aminotransferase level (n = 21, 43.8%), increased bilirubin level (n = 22, 45.8%), decreased white blood cell (WBC) count (n = 27, 56.3%), decreased platelet count (n = 31, 64.6%), anemia (n = 15, 31.3%), fatigue (n = 23, 47.9%), diarrhea (n = 7, 14.6%), nausea (n = 18, 37.5%), and vomiting (n = 9, 18.8%).